Objective: The development of immunotherapy for malignancy is greatly limited by the
characteristic weak antigenicity of tumors. The primary goal of this study was to circumvent …

Several studies have shown that vaccine therapy using dendritic cells (DCs) pulsed with
specific tumor antigen peptides can effectively induce antitumor immunity. Peptide-pulsed …

Dendritic cells (DC) are the most powerful antigen-presenting cells that induce and maintain
primary immune responses in vitro and in vivo. The development of protocols for the ex vivo …

Immune regulation has been shown to be involved in the progressive growth of some
murine tumours. Interruption of immune regulatory pathways via CTL‐associated antigen‐4 …

Early efforts toward human cancer im-munotherapy were hindered by the absence of
identified antigens to target by vaccination or cell therapy. In the past decade, studies …

Novel antigen-presenting cells (APCs) were generated using cultured dendritic cells (DCs)
and amplified tumor mRNA, and the potential of tumor antigen-reactive T cell induction by …

Cancer vaccines are a promising approach to treating tumors or preventing tumor relapse
through induction of an immune response against tumor-associated antigens (TAA). One …

Induction of potent and sustained antitumor immunity depends on the efficient activation of
CD8+ and CD4+ T cells. Immunization using dendritic cells loaded with tumor antigens …

Evaluation of: Elia L, Aurisicchio L, Facciabene A et al. CD4+ CD25+ regulatory T-cell
inactivation in combination with adenovirus vaccines enhances T-cell responses and …